🇺🇸 FDA
Pipeline program

Irinotecan liposomes combined with cisplatin/carboplatin

2024-101

Approved small_molecule active

Quick answer

Irinotecan liposomes combined with cisplatin/carboplatin for Neuroendocrine Tumors is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Neuroendocrine Tumors
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials